Abstract
INTRODUCTION

49
A better understanding of cervical carcinogenesis has led to the development of several 50 prevention approaches that target high-risk human papillomavirus (HPV), the causative agent 51 of cervical cancer and one of the most common sexually transmitted infections [1] . The to a more severe lesion within the next screening round than those with normal cytology [9, 74 10], but the elevated risk may not warrant direct referral to diagnostic colposcopy with biopsy.
75
Management guidelines for these women differ among developed countries, and determining 76 the optimal follow-up approach as well as the threshold to prompt colposcopy referral 77 remains a challenge. For example, decision-makers in Norway updated the screening 78 guidelines for women with either ASC-US or LSIL in July 2014 to include re-testing a 79 woman's initial cytology sample for the presence of high-risk HPV (i.e., reflex HPV testing).
80
Women testing positive for high-risk HPV are recommended to return 6 to 12 months later 81 for repeat testing to identify persistent high-risk HPV infections or cytologic abnormalities. 
MATERIALS AND METHODS
101
Analytic approach 102 We adapted a previously developed microsimulation model [20, 21] (Table 1 ). In addition, we explored the impact of restricting the scope of 161 the analysis to include only direct medical costs or broadening the scope of the analysis to 162 include productivity losses associated with sick leave after precancer and cancer treatments. Norway, for a willingness-to-pay threshold of $100,000 per QALY gained, the preferred (i. referrals and precancer treatments compared to current levels, both of which may be subject 294 to short-term capacity constraints in Norway. In contrast, the HPV genotyping strategies 295 require only a moderate increase in resource use, with nominal compromises in health gains.
296
To our knowledge, this is the first analysis to investigate the impact of using novel found that resource requirements vary substantially.
315
Our study has several implications for resource utilization. First, the model used in 316 this analysis is one of the only natural history models that explicitly accounts for the role of gained that far exceeded current willingness-to-pay threshold recommendations in Norway.
327
In Norway, and other countries with similar epidemiologic characteristics and relative costs, 328 the cost savings associated with reducing colposcopy referrals for HPV-negative LSILs may 329 outweigh the incremental benefit achieved by referring these women to colposcopy. of Oslo) throughout analysis. The study has used data from the Cancer Registry of Norway.
379
The interpretation and reporting of these data are the sole responsibility of the authors, and no 380 endorsement by the Cancer Registry of Norway is intended nor should be inferred. 
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